FHND1002
Phase 2Small molecule
FHND1002 is one of 82 small molecule programs targeting Treatment. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
81
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
332 competitors in Treatment
#DrugCompanyPhaseTrials
1Dexilant
TakedaPreclinical
Lamprene
NovartisPreclinical
Emtriva
GileadPreclinical
Alfenta
Jazz PharmaceuticalsPreclinical
Valium
Akero TherapeuticsPreclinical
FHND1002
JJiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Phase 2
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Sirturo
WWim Janssens
Preclinical
Nerlynx
PPuma Biotechnology, Inc.
Preclinical
Lotemax
PPharmos
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment1 trial
FHND1002 for ALS Treatment: Phase 2
Not yet recruiting·JJiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.·Phase 2·NCT07138014·180 enrolled
Adult1 trial
Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults
Enrolling by invitation·JJiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.·Phase 1·NCT06782958·72 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FHND1002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details